This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The RTS,S Cinical Trials Partnership. first results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. published online, 10.1056/nejmoa1102287 (18 October 2011).
Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS, S vaccine. Hum. Vaccin. 6, 90–96 (2010).
Stewart, V.A. et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75, 2283–2290 (2007).
Bojang, K.A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927–1934 (2001).
Good, M.F. Our impasse in developing a malaria vaccine. Cell. Mol. Life Sci. 68, 1105–1113 (2011).
Barry, A.E., Schultz, L., Buckee, C.O. & Reeder, J.C. et al. Contrasting population structures of the genes encoding ten leading malaria vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One 4, e8497 (2009).
Bejon, P. et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359, 2521–2532 (2008).
Asante, K.P. et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect. Dis. 11, 741–749 (2011).
Moorthy, V., Reed, Z. & Smith, P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 25, 5115–5123 (2007).
Alonso, P.L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012–2018 (2005).
A.V.S.H. has collaborated with GlaxoSmithKline Biologicals in assessment of RTS,S vaccines and is a developer of other malaria vaccine candidates.
About this article
Cite this article
Mixed results for a malaria vaccine. Nat Med 17, 1560–1561 (2011). https://doi.org/10.1038/nm1211-1560
This article is cited by
Nature Reviews Microbiology (2013)